On the 17th, Organoid Science (CEO Jong-man Yoo) signed a contract with JW Pharmaceutical for ‘establishment of an organoid-based new drug development platform and joint research’ to strengthen non-clinical translational research.
Through this business agreement, the two companies will jointly develop an R&D platform that actively utilizes organoid technology for new drug development based on continued cooperation.
Organoid Science will develop an organoid model using tissue collected from patients, and JW Pharmaceutical will then build a platform that accumulates the information and turns it into a database.
In addition, JW Pharmaceutical’s New Drug Research Center, research corporation C&C New Drug Research Institute, and JW Creagene, a research corporation of JW New Drug, plan to pursue joint research with Organoid Science to strengthen the pipeline of new drugs being developed by each company. We plan to increase the success rate of future clinical trials by analyzing drug efficacy evaluation and mechanism of action using organoid models (constructed from organs) that are the target of each new drug candidate, and will also be used for expansion of indications and exploratory research for new substances. .
Organoid Science’s organoid-based efficacy evaluation technology, which will be used in joint research with JW Group, can be used at each stage of development for drugs in various fields, including anticancer drugs, by utilizing the high human body mimicry of organoids, and shows a high degree of clinical agreement with clinical results. Its characteristic is that it is fully predictable.
JW Pharmaceutical CTO (Chief Technology Officer) Chan-hee Park said, “We have been strengthening our new drug development capabilities by building our own genome informatics platforms ‘Clover’ and ‘Jewelry’ centered on non-clinical (cell line, animal) models.” He said, “In the future, with the addition of the organoid platform, we will further expand the patient-tailored innovative new drug pipeline in the three major fields of anticancer, immunity, and regeneration, which are JW’s R&D directions.”
With this joint research agreement, Organoid Science plans to focus more on advancing organoid-based efficacy evaluation technology to build an R&D platform.
Jongman Yoo, CEO of Organoid Science, said, “The innovative technology of the organoid-based platform accumulated by Organoid Science is expected to create high synergy by combining with the research and development capabilities of JW Group, which has abundant experience and organizational capabilities in various fields of new drug development. “We will strengthen cooperation so that the competitiveness of both companies can lead to groundbreaking results in the development of customized innovative new drugs,” he said.
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asia Innovation Hub Pangyo Techno Valley 2022’ news